Scientists raise concerns over new Alzheimer’s drugs ahead of regulator decision

19 February 2024

Professor Rob Howard (UCL Psychiatry) believes the benefits of taking the 'miracle' drugs, such as donanemab, which is currently awaiting approval in the US and UK, are 'literally too small to be noticeable' by a patient or doctor.